High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia

Summary

The purpose of this study is to compare efficacy and safety of add-on treatment with a moderately high dose of D-serine, an NMDA-glycine site agonist, in young, recent onset schizophrenia patients who suffer from significant symptoms despite treatment with antipsychotics.

Timeline

Start

2011-11

Primary completion

2013-10

Completion

2014-10

Drugs

Indications